A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.

We observed no differences by PCR ( Figure 2A ), but with TCID 50 , the MHAA4549A arms showed a trend toward faster viral load clearance; however, this was not statistically significant ( Figure 2B ).

also in 53,322 other papers